|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
$620
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
Cancer Center Support Grant
|
5P30CA014599-42
|
$4,385,423
|
$43,854
|
LE BEAU, MICHELLE
|
UNIVERSITY OF CHICAGO
|
|
Chile Gallbladder Cancer Study
|
ZIA CP010218-10540
|
$3,032,450
|
$1,212,980
|
Koshiol, Jill
|
DCEG (NCI)
|
|
Antigen-specific T-cell Activation, Application to Vaccines for Cancer and AID
|
ZIA SC 004020
|
$2,592,300
|
$259,230
|
Berzofsky, Jay
|
CCR (NCI)
|
|
Cancer Center Support Grant (CORE) Renewal
|
5P30CA023168-38
|
$1,860,000
|
|
RATLIFF, TIMOTHY
|
PURDUE UNIVERSITY
|
|
Building on the success of the adoptive immunotherapy of cancer
|
ZIA BC 010763
|
$1,562,883
|
$312,577
|
Restifo, Nicholas
|
CCR (NCI)
|
|
Statistical Methods for Integrative Genomics in Cancer
|
5P01CA196569-03
|
$1,494,177
|
|
THOMAS, DUNCAN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Biological mechanisms involved with PDT in the treatment of MPM
|
5P01CA087971-15
|
$1,354,550
|
|
BUSCH, THERESA
|
UNIVERSITY OF PENNSYLVANIA
|
|
Protein Structure
|
ZIA BC 010348
|
$1,090,490
|
$272,623
|
Wlodawer, Alexander
|
CCR (NCI)
|
|
Consequences of chronic Interferon-gamma expression on the host
|
ZIA BC 009283
|
$1,020,013
|
$1,020,013
|
Young, Howard
|
CCR (NCI)
|
|
Integrative approaches to elucidate p53 transcriptional networks during carcinogenesis
|
5R35CA197591-04
|
$977,640
|
|
ATTARDI, LAURA
|
STANFORD UNIVERSITY
|
|
Role of inflammation, innate resistance, and immunity in carcinogenesis
|
ZIA BC 010793
|
$840,626
|
$168,125
|
Trinchieri, Giorgio
|
CCR (NCI)
|
|
Cellular molecular biologics in clinical cancer research
|
5K12CA076931-20
|
$796,188
|
|
SCHUCHTER, LYNN
|
UNIVERSITY OF PENNSYLVANIA
|
|
ENIGMA Center for Worldwide Medicine, Imaging & Genomics
|
5U54EB020403-05
|
$790,391
|
|
THOMPSON, PAUL
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
End-of-Life Care for Adolescents and Young Adults with Cancer: An Evaluation of Care and Development of Patient-Centered Quality Measures
|
1R01CA218651-01A1
|
$671,298
|
|
MACK, JENNIFER
|
DANA-FARBER CANCER INST
|
|
Clinical Pregnancy Outcomes in Adolescent and Young Adult Female Cancer Survivors
|
5R01CA204258-02
|
$626,296
|
|
NICHOLS, HAZEL
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Naive T cells in Cancer Immune Evasion and Immunotherapy
|
5R01CA217510-02
|
$625,446
|
|
ZOU, WEIPING
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Redox imaging for breast cancer prognosis
|
5R01CA191207-04
|
$622,003
|
|
LI, LIN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Less Pain, Less Fuss, Right Now! and Make It Count!- Multilevel Interventions for Patient, Parent, and Practice to Enhance Provider Recommendations for HPV Vaccination
|
1R01CA217889-01A1
|
$617,672
|
|
JACOBSON, ROBERT
|
MAYO CLINIC ROCHESTER
|
|
Signal Transduction Events and the Regulation of Cell Growth
|
ZIC SC 006743
|
$609,397
|
$6,094
|
Trepel, Jane
|
CCR (NCI)
|
|
Circulating Biomarker Consortium for Pancreatic Cancer Early Detection
|
5U01CA210171-03
|
$602,403
|
|
WOLPIN, BRIAN
|
DANA-FARBER CANCER INST
|
|
Analysis of drug response in organoids and mouse models
|
5R01CA196662-03
|
$597,601
|
|
SHEN, MICHAEL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Schwann Cell Reprogramming and Cancer Perineural Invasion
|
5R01CA219534-02
|
$576,166
|
|
WONG, RICHARD
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Surgical Oncology Basic Science and Translational Research Training Program
|
5T32CA009621-30
|
$559,406
|
|
GILLANDERS, WILLIAM
|
WASHINGTON UNIVERSITY
|
|
T Cell Alternative p38 Activation Pathway
|
ZIA BC 010774
|
$559,148
|
$139,787
|
Ashwell, Jonathan
|
CCR (NCI)
|
|
Clinical Interventional Studies of HIV Reservoirs
|
ZIA BC 011464
|
$554,151
|
$83,123
|
Maldarelli, Frank
|
CCR (NCI)
|
|
Oncology Training Grant
|
5T32CA009338-40
|
$544,263
|
|
BYRD, JOHN
|
OHIO STATE UNIVERSITY
|
|
Lymphoma Studies
|
ZIA SC 006741
|
$486,708
|
$9,734
|
Wilson, Wyndham
|
CCR (NCI)
|
|
Cancer Immunology Training Grant
|
5T32CA207021-03
|
$472,152
|
|
WUCHERPFENNIG, KAI
|
DANA-FARBER CANCER INST
|
|
Redox Modification and Targeting of Mutant KRas in Cancer
|
1R01CA227849-01
|
$447,549
|
|
CARROLL, KATE
|
SCRIPPS FLORIDA
|
|
(PQ10) Enhancing responses to immune checkpoint blockade in melanoma via modulation of the microbiome
|
1R01CA219896-01A1
|
$429,943
|
|
WARGO, JENNIFER
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Enhancing Tumor Antigen Presentation with Complement Targeted Nanoparticles
|
1R15CA227740-01
|
$428,365
|
|
KULLBERG, MAX
|
UNIVERSITY OF ALASKA ANCHORAGE
|
|
Identify the DNA Adduct and Associated Metabolic Alterations in Bladder Cancer of Smokers
|
1R01CA216426-01A1
|
$427,819
|
|
PUTLURI, NAGIREDDY
|
BAYLOR COLLEGE OF MEDICINE
|
|
Immune reconstitution following autologous and allogeneic stem cell transplant
|
ZIC BC 010934
|
$420,830
|
$126,249
|
Hakim, Frances
|
CCR (NCI)
|
|
Tissue-specific tumor suppressor effects of p53
|
5R01CA200256-04
|
$409,185
|
|
MANFREDI, JAMES
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors
|
1R01CA227388-01
|
$407,175
|
|
VAN ALLEN, ELIEZER
|
DANA-FARBER CANCER INST
|
|
FANCM in repair of stalled replication forks
|
5R01CA217991-02
|
$395,738
|
|
SCULLY, RALPH
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Viral Oncology Training Grant
|
5T32CA009111-40
|
$391,340
|
|
CULLEN, BRYAN
|
DUKE UNIVERSITY
|
|
Oncogenic pathways and therapeutic targets in T cell acute lymphoblastic leukemia
|
5R01CA211734-02
|
$391,163
|
|
LANGENAU, DAVID
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Modeling pediatric glioma in human ES cells:mechanistic and therapeutic insights
|
5R01CA208405-03
|
$391,150
|
|
TABAR, VIVIANE
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Colitis, Colon Cancer and the NLR Family
|
5R01CA156330-07
|
$383,978
|
|
TING, JENNY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Progesterone Signaling and Blockade in Human Breast Tumorigenesis and Prevention
|
5R01CA192124-04
|
$377,020
|
|
KHAN, SEEMA
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
Syndecan-1 (CD138) and its synstatins: targeting invasion, survival and angiogenesis in myeloma
|
5R01CA212413-02
|
$369,666
|
|
RAPRAEGER, ALAN
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
Phospholipase-activated theranostics for PDT of breast cancer
|
5R01CA201328-03
|
$368,288
|
|
POPOV, ANATOLIY
|
UNIVERSITY OF PENNSYLVANIA
|
|
Pathway Choice of DNA Double-Strand Break Repair
|
5R01CA162804-07
|
$361,898
|
|
CHEN, DAVID
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Exosomes and platinum-induced peripheral neuropathy
|
1R01CA219829-01A1
|
$358,545
|
|
ZHANG, ZHENG GANG
|
Henry Ford Health System
|
|
Therapeutic targeting of Kras-driven Lung Adenocarcinoma
|
5R01CA206367-03
|
$357,994
|
|
FIELDS, ALAN
|
MAYO CLINIC JACKSONVILLE
|
|
Treatment of Castration-resistant Prostate Cancer (CRPC)
|
5R01CA196835-03
|
$354,563
|
|
LIU, XIAOQI
|
PURDUE UNIVERSITY
|
|
Protease activated receptor-2 (PAR-2) signaling and metastatic ovarian cancer
|
5R01CA196988-02
|
$353,419
|
|
ANTALIS, TONI
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
The Role of MMSET in the Pathogenesis and Progression of Lymphoid Malignancy
|
5R01CA195732-03
|
$348,844
|
|
LICHT, JONATHAN
|
UNIVERSITY OF FLORIDA
|
Total relevant funding to Interferon for this search: $4,542,084
|